Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2016 February;107(1) > Minerva Medica 2016 February;107(1):70-6

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA MEDICA

A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Frequency: Bi-Monthly

ISSN 0026-4806

Online ISSN 1827-1669

 

Minerva Medica 2016 February;107(1):70-6

    REVIEWS

Long noncoding RNA GAS5 can predict metastasis and poor prognosis: a meta-analysis

Wei SONG, Kai WANG, Run-Jin ZHANG, Qi-Xin DAI, Shu-Bing ZOU

Department of Hepatobiliary Surgery, The Second affiliated hospital of Nanchang University, Nanchang, China

INTRODUCTION: Growth arrest-specific 5 (GAS5), a newly discovered long-noncoding RNAs (lncRNAs), has been reported to be down-regulated in multiple cancers. This meta-analysis aims to identify the potential value of GAS5 as a biomarker of cancer metastasis and prognosis.
EVIDENCE ACQUISITION: We searched the MEDLINE, EMBASE and Cochrane Library databases. This meta-analysis collected all relevant studies and explored the association of lncRNA GAS5 with overall survival (OS), lymphnode metastasis (LNM), and distant metastasis (DM).
EVIDENCE SYNTHESIS: Four studies were eligible for analysis, which included 328 patients. Meta-analysis revealed that low levels of GAS5 expression could predict poor OS in multiple cancers (pooled Hazard Ratio [HR]: 0.38, 95% confidence interval [CI]: 0.26-0.54, P<0.00001). Moreover, compared with high GAS5 expression, low GAS5 expression was correlated with LNM (pooled HR: 4.03, 95% CI: 1.93-8.41, P=0.0002) and DM (pooled HR: 10.17, 95% CI: 1.26-82.31, P=0.03).
CONCLUSIONS: lncRNA GAS5 may potentially serve as a novel biomarker for cancer metastasis and prognosis.

language: English


FULL TEXT  REPRINTS

top of page